Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

Jun Sung Moon1,*, Il Rae Park1,*, Hae Jin Kim1, Choon Hee Chung1, Kyu Chang Won1, Kyung Ah Han4, Cheol-Young Park2, Jong Chul Won6, Dong Jun Kim7, Gwan Pyo Koh1, Eun Sook Kim3, Jae Myung Yu10, Eun-Gyoung Hong11, Chang Beom Lee12, Kun-Ho Yoon13

1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, 2Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, 3Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, 4Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, 5Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 6Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, 7Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, 8Department of Internal Medicine, Jeju National University College of Medicine, Jeju, 9Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 10Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, 11Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, 12Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, 13Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Background: This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination.

Methods: In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n = 283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998).

Results: Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; \( P < 0.0001 \)). The proportion of patients achieving HbA1c <7% was higher in the triple combination group at week 52 (32.14% vs. 8.51% in placebo; odds ratio, 5.62; \( P < 0.0001 \)). Evogliptin significantly reduced the fasting glucose levels and mean daily glucose levels with improvement in homeostatic model assessment of \( \beta \)-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; \( P = 0.0138 \)). Adverse events were similar between the groups, and no serious adverse drug reactions were reported in the evogliptin group.

Conclusion: Long-term triple combination with evogliptin added to DAPA/MET showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks and was well tolerated.

Keywords: Dapagliflozin; Diabetes mellitus, type 2; Dipeptidyl-peptidase IV inhibitors; Drug therapy, combination; Metformin
INTRODUCTION

Type 2 diabetes mellitus (T2DM) is an increasingly prevalent global health challenge that affected more than 500 million adults in 2021 [1]. Diabetes is a progressive chronic disease and leads to various vascular complications such as retinopathy, peripheral neuropathy, renal failure, or cardiovascular diseases. To prevent these tragic courses, strict and earlier glycemic control has shown significant benefits in mitigating diabetic complications [2], including overall mortality [3]. However, despite newly developed glucose-lowering agents with novel modes of action for a decade, it remains still difficult to achieve the glycemic targets in real-world settings [4]. Earlier combination therapy is an emerging strategy to provide a long-lasting therapeutic option for patients with T2DM [5]; however, add-on therapy should be immediately considered if glycemic target level is not reached. Synergism with diverse pharmacologic actions could treat complicated pathophysiology of T2DM while simultaneously compensating for side effects [6,7].

Recently, dapagliflozin (DAPA), a first-in-class sodium-glucose cotransporter 2 (SGLT2) inhibitor became a mandatory prescription for T2DM patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [8-10]. SGLT2 inhibitors improved hyperglycemia without stimulating insulin secretion, which led to increased β-cell function, reduced insulin resistance, and weight loss [10]. However, some studies have shown that SGLT2 inhibitors paradoxically increase endogenous glucose production with glucagon secretion [11,12].

Evogliptin, a novel dipeptidyl peptidase 4 (DPP4) inhibitor, is more commonly used in clinical practice for its potent glucose-lowering effects without any serious adverse events, especially on glycemic variability in patients with T2DM [13]. DPP4 inhibitors increase active plasma glucagon-like peptide 1 (GLP-1) levels, resulting in not only increased insulin secretion but also suppressed glucagon secretion from the α-cell. Thus, in cases of treatment failure after DAPA and metformin (MET) combination therapy, DPP4 inhibitor add-on treatment may have synergism with complementary actions [14-16].

Based on this hypothesis, we evaluated the glycemic efficacy and safety of evogliptin add-on therapy for 24 and 52 weeks in patients with inadequately controlled T2DM from DAPA/MET therapy.

METHODS

Study participants

The eligible patients were those aged ≥19 years with T2DM treated with combination therapy of DAPA/MET or other SGLT2 inhibitors for at least 8 weeks. Patients with glycosylated hemoglobin (HbA1c) levels between 7.0% and 10.5%, fasting plasma glucose (FPG) levels less than 270 mg/dL, and body mass index (BMI) between 18.5 and 40 kg/m² were recruited in this trial. Full inclusion and exclusion criteria of this trial are listed in the ‘Inclusion/exclusion criteria’ of Supplementary Methods. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice, and the study protocol. The study was approved by the Institutional Review Boards of Yeungnam University Hospital (IRB no. 2019-09-046-045) and each participating center. Participants were those who signed a written informed consent and agreed to participate in the trial after fully understanding the detailed explanation of this study.

Study design and procedure

This was a multicenter randomized double-blind placebo-controlled parallel phase 3 clinical trial of 24 weeks of treatment and a long-term extension period of 28 weeks (ClinicalTrials.gov NCT04170998).

All participants maintained with a stable dose of DAPA 10 mg and MET ≥1,000 mg/day during run-in period. After a run-in period, eligible individuals were randomly assigned in a 1:1 ratio to receive oral evogliptin (5 mg) or placebo once daily. These medications were added to the DAPA/MET combination for 24 weeks. Patients who provided written informed consent participated in the 28 weeks of site and patient blind extension treatment periods. The ‘Safety set’ included subjects who have administrated the investigational product at least once after randomization and whose safety-related data have been evaluated at least once after administration.

Endpoints

The primary efficacy endpoint was the change in the HbA1c level (%) from the baseline after 24 weeks. The key secondary endpoint was the change in the HbA1c levels (%) from the baseline after 52 weeks. Some patients achieved HbA1c <7% and <6.5% at weeks 24 and 52, respectively, showing changes in FPG levels, mean daily glucose (MDG) levels, and postprandial glucose (PPG) levels at 2 hours after breakfast/lunch/din-
ner from the baseline to weeks 24 and 52. Other secondary endpoints are listed in the 'Secondary endpoints' of Supplementary Methods.

The safety outcome reported during the clinical trial period included treatment-emergent adverse event, adverse drug reaction (ADR), serious adverse event, serious ADR, and adverse event of special interest (AESI). Laboratory assessment included hematology, blood chemistry, urinalysis, and electrocardiography (ventricular rate, PR interval, QRS, QT/QTc) for each treatment group during the main trial and the extension period.

**Statistical analysis**

Given the primary efficacy endpoint, the difference between the evogliptin group compared with placebo group was assumed to be 0.35, and the standard deviation of each group was assumed to be 0.8. Assuming randomization at a 1:1 ratio with a 90% power at a 0.05% level of significance, 110 participants were required for each group. A total of 276 participants, 138 in each group, were enrolled to account for the 20% dropout rate.

Efficacy analyses were based on the full analysis set population, which consisted of all randomized patients who received at least one dose of the study medication and had a baseline measurement and at least one post-baseline measurement. The mixed effect model repeated measure (MMRM) analysis was performed to evaluate the superiority of evogliptin compared with the placebo in the primary efficacy endpoint (the change in the HbA1c level [%] after 24 weeks). The MMRM included the treatment group, the visit, the interaction between the treatment group and the visit, and severity (less than/greater than or equal to 8.0% of HbA1c level), which was a stratification factor, as fixed effects.

For the analysis of secondary efficacy endpoints, the MMRM and generalized linear mixed model (logistic GLMM) were constructed, or an analysis of covariance (ANCOVA) was performed.

The analysis model was evaluated using least square (LS) mean difference between treatment groups. The 95% confidence interval (CI) and P value corresponding to the LS mean and standard error (SE) of each treatment group and the LS mean difference between the treatment groups were presented. Furthermore, odds ratio, SE, 95% CI, and P value were presented as analysis results.

Safety analysis for comparison of incidence rates between treatment groups was performed using the chi-square test or Fisher's exact test. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).

**RESULTS**

**Demographic characteristics of participants**

The study disposition is summarized in Fig. 1. The trials were conducted in 34 centers of South Korea with 333 screened patients and 283 randomized patients (142 participants in the placebo group and 141 participants in the evogliptin group). In this study, 262 (92.58%) participants completed the main 24 weeks of the study, while 21 (7.42%) participants were discontinued (12 in the placebo group and nine in the evogliptin group). Among the 283 randomized participants, 234 were in the 28-week extension study (112 in the placebo group and 122 in the evogliptin group). Overall, 110 participants in the placebo group and 119 participants in the evogliptin group completed the 52-week trial.

The baseline demographics of the participants were similar between the two groups (Table 1). The mean age of the participants was 56.65 years, 59.72% of which were males (n=169). The mean body weight and BMI at baseline were 70.91 kg and 25.93 kg/m², respectively. The average disease duration of T2DM was 10.29 years. The mean HbA1c level was 7.91%, and the mean estimated glomerular filtration rate was 93.05 mL/min/1.73 m².

**Primary efficacy endpoint**

Evogliptin treatment significantly decreased HbA1c levels at week 24 compared with the baseline (LS mean±SE, –0.69%±0.05%) and was superior compared to placebo (–0.04%±0.05%). The LS mean difference between the two groups at 24 weeks was –0.65±0.07 (95% CI, –0.79 to –0.51) (P<0.0001) (Fig. 2).

**Secondary efficacy endpoint**

Glucose-lowering effects of evogliptin were maintained in the 28-week extension period. The LS mean change (±SE) in HbA1c levels compared with the baseline was –0.59%±0.06% and was superior compared to placebo (–0.04%±0.05%). The LS mean difference between the two groups at 24 weeks was –0.65±0.07 (95% CI, –0.79 to –0.51) (P<0.0001) (Fig. 2).

The proportion of participants who achieved HbA1c <7% and <6.5% was significantly higher in the evogliptin group.
Randomized
\( (n=283) \)

Placebo \( (n=142) \)
- Not treated \( (n=1) \)

Evogliptin \( (n=141) \)

Discontinued \( (n=9) \)
- Consent withdrawal \( (n=5) \)
- Violation on inclusion/exclusion criteria \( (n=1) \)
- Adverse events \( (n=1) \)
- Protocol deviation \( (n=1) \)
- Lost to follow-up \( (n=1) \)

Entered long-term treatment period
\( n=112 \)

Completed long-term treatment period
\( n=110 \)

Safety set \( (n=141) \)
- Full analysis set \( (n=141) \)
- Per-protocol set \( (n=129) \)

Discontinued \( (n=12) \)
- Consent withdrawal \( (n=5) \)
- Violation on inclusion/exclusion criteria \( (n=4) \)
- Adverse events \( (n=2) \)
- Withdrawal by the investigator \( (n=1) \)

Placebo \( (n=1) \)

Not treated \( (n=1) \)

Discontinued \( (n=2) \)
- Prohibited medication \( (n=1) \)
- Treatment failure \( (n=1) \)

Safety set \( (n=141) \)
- Full analysis set \( (n=140) \)
- Per-protocol set \( (n=127) \)

Discontinued \( (n=3) \)
- Consent withdrawal \( (n=1) \)
- Adverse events \( (n=1) \)
- Lost to follow-up \( (n=1) \)

\( n=130 \)

\( n=112 \)

\( n=110 \)

\( n=132 \)

\( n=122 \)

\( n=119 \)

Fig. 1. Patient disposition.

Fig. 2. Primary endpoint as change in the glycosylated hemoglobin (HbA1c) level. Time course of adjusted mean change in the HbA1c level from the baseline (A) and adjusted mean change in the HbA1c level from baseline to weeks 24 and 52 (B). Data expressed as mean and 95% confidence interval (CI). SE, standard error. \( ^*P<0.0001 \) between evogliptin and placebo.

than in the placebo group at weeks 24 and 52 (Fig. 3A). The FPG and PPG effect at 2 hours (except for at breakfast; \( P = 0.0519 \)) also significantly differed between the evogliptin and placebo groups. The LS mean FPG level in the evogliptin group...
significantly decreased to –11.30±1.72 at week 24 and –8.66±1.86 at week 52, while the LS mean FPG level in the placebo group changed minimally compared with the baseline (Fig. 3B). The LS mean difference for the change of the FPG level between the two groups was –14.61±2.41 (95% CI, –19.34 to –9.87; \( P < 0.0001 \)) at week 24 and –7.28±2.67 (95% CI, –12.53 to –2.02; \( P = 0.0069 \)) at week 52 (Fig. 3C). Evogliptin treatment was also superior to placebo for reduction in the MDG levels during the study period. The LS mean differences between the groups at weeks 24 and 52 were –13.18±3.41 (95% CI, –19.91 to –6.45; \( P = 0.0002 \)) and –11.77±3.70 (95% CI, –19.06 to –4.47; \( P = 0.0017 \)), respectively (Fig. 3D).

Among exploratory indexes related with glucose metabolism, evogliptin treatment improved homeostatic model assessment of β-cell function (HOMA-β) as an insulin secretory function index during the entire study period, whereas almost no changes were seen in the placebo group (Fig. 3E). However, there were no differences in HOMA-insulin resistance, quantitative insulin sensitivity check index (QUICKI), and glucagon levels between the two groups at weeks 24 and 52. Additional and detailed efficacy endpoints are provided in the Supplementary Table 1.

### Safety outcomes

Table 2 summarizes the safety outcomes in this study. Safety analysis was performed on the 'Safety set,' and 282 subjects
Fig. 3. Secondary endpoint. Proportion of glycemic achievement at week 52 (A), time course of adjusted mean change in the fasting plasma glucose (FPG) level from baseline (B), adjusted mean change in the FPG level from baseline to week 52 (C), adjusted mean change in the mean daily glucose (MDG) level (D) and homeostatic model assessment of β-cell function (HOMA-β) from baseline to week 52 (E). (B) Data expressed as mean and 95% confidence interval (CI). OR, odds ratio; SE, standard error. \(^{a}P<0.0001, {b}P<0.01\) between placebo and evogliptin.
(141 in the placebo group, 141 in the evogliptin group) were included. During the main and extension studies, most adverse events were mild or moderate in both groups. The rates of ADRs during the 52-week treatment in both groups were 2.84%. There was no serious ADR, while those observed did not lead to discontinuation during the trial.

The hypoglycemia developed during the 52-week study period was asymptomatic hypoglycemia, which occurred as a single event in one participant of each group (0.71%) (Table 2). The rates of AESI were also the same (2.84%), and arthralgia and increased lipase levels were observed in both groups. The event numbers for treatment-emergent adverse events/AESIs and details of AESI was described in the Supplementary Table 2.

**DISCUSSION**

In this study, compared with placebo, evogliptin add-on treatment showed a significant HbA1c reduction at 52 weeks in poorly controlled T2DM patients using DAPA/MET. Secondary efficacy outcomes such as FPG, PPG, and MDG levels measured through 7-point self-monitoring blood glucose were also significantly improved. The proportion of patients who achieved target HbA1c (<6.5% and 7.0%) was higher in the evogliptin group than in the placebo group. Adding evogliptin was confirmed to be safe, with no differences in any adverse events between groups. These results were attributed to the improvement of β-cell function after 52 weeks of evogliptin treatment compared with placebo treatment.

When combination therapy with SGLT2 inhibitors and MET failed to achieve the target glycemic goal, current guidelines recommended to promptly initiate add-on therapy for preventing clinical inertia [17]. Many considerations such as glucose-lowering potency, weight changes, and the risk of hypoglycemia should be required for optimal “patient-centered” decision in this sequence. Among the oral hypoglycemic agents, DPP4 inhibitors are an attractive option for its additive and complementary actions to SGLT-2 inhibitors [7,18]. Since the glucose-lowering effects of SGLT2 inhibitors do not interact with drugs that improve β-cell function or insulin sensitivity, combination therapy might result in additive efficacy. DPP4 inhibitors improve pancreatic β-cell function and post-prandial hyperglycemia [13,19]. Evogliptin has consistently shown potent glycemic efficacy as mono- and combination therapy and was confirmed with a continuous monitoring system to significantly reduce glycemic variability [13]. This study also confirmed that an additive benefit of evogliptin was attributed to the improvement of HOMA-β, a surrogate marker of β-cell function. Therefore, evogliptin with SGLT2 inhibitors has potential benefits on both the durable glycemic control and cardiovascular-renal complications [16,20].

Evogliptin was a safe option as a third combination after DAPA/MET treatment failed. No serious ADRs were observed, and ADRs considered to have a causal relationship with evogliptin occurred in only four participants (2.84%) over 52 weeks. One case was reported as hypoglycemia and others reported as abnormal lipase levels. All these reported drug-related adverse events were mild or moderate and did not cause discontinuation of evogliptin. A few cases of acute pancreatitis associated with the use of DPP4 inhibitors were reported, revealing that DPP4 inhibitors should not be restarted, despite insufficient data of a causal relationship. In this study, two asymptomatic cases with mildly elevated lipase levels were reported in the evogliptin group, but no pancreatitis was reported, which does not suggest that T2DM patients with evogliptin

---

**Table 2. Safety outcomes**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo $(n=141)$</th>
<th>Evogliptin $(n=141)$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TEAEs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>32 (22.70)</td>
<td>39 (27.66)</td>
<td>0.4105</td>
</tr>
<tr>
<td>52 weeks</td>
<td>48 (34.04)</td>
<td>50 (35.46)</td>
<td>0.9005</td>
</tr>
<tr>
<td><strong>Adverse drug reaction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>4 (2.84)</td>
<td>3 (2.13)</td>
<td>1.0000</td>
</tr>
<tr>
<td>52 weeks</td>
<td>4 (2.84)</td>
<td>4 (2.84)</td>
<td>1.0000</td>
</tr>
<tr>
<td><strong>Serious adverse events</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>6 (4.26)</td>
<td>5 (3.55)</td>
<td>1.0000</td>
</tr>
<tr>
<td>52 weeks</td>
<td>7 (4.96)</td>
<td>8 (5.67)</td>
<td>1.0000</td>
</tr>
<tr>
<td><strong>Serious adverse drug reaction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>52 weeks</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td><strong>AESI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>3 (2.13)</td>
<td>4 (2.84)</td>
<td>1.0000</td>
</tr>
<tr>
<td>52 weeks</td>
<td>4 (2.84)</td>
<td>4 (2.84)</td>
<td>1.0000</td>
</tr>
<tr>
<td><strong>Hypoglycemia, asymptomatic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>1 (0.71)</td>
<td>1 (0.71)</td>
<td>1.0000</td>
</tr>
<tr>
<td>52 weeks</td>
<td>1 (0.71)</td>
<td>1 (0.71)</td>
<td>1.0000</td>
</tr>
</tbody>
</table>

Values are presented as number (%). Difference between treatment groups was analyzed using the Fisher’s exact test. TEAE, treatment-emergent adverse event; AESI, adverse event of special interest.
require a lipase screening test. It is important to monitor patients with symptoms or a history of acute pancreatitis [21].

A change in was observed in glucagon levels following treatment, contrary to what we expected; however, there was no statistical difference between the groups.

When participants were categorized according to the baseline HbA1c level, glucagon levels were also similar in both groups from subgroup analysis (data not shown). It was hypothesized that disadvantages of SGLT2 inhibitors such as increased caloric intake and hepatic glucose production (HGP) might be mitigated by incretin-based treatment. SGLT2 inhibitors induce glycosuria by inhibiting glucose reabsorption in the renal proximal tubule [22,23]. This mechanism reduces blood glucose levels and decreases insulin levels followed by an increase in glucagon levels [12]. Theoretically, DPP4 inhibitor can act complementary to the SGLT2 inhibitor by reducing glucagon levels, but we did not find significant reductions of glucagon levels by evogliptin add-on compared with placebo. Paradoxical increases in HGP and glucagon levels have been reported in studies on short-term SGLT2 inhibitor treatment for few weeks or even several hours. However, little is known regarding the glucagon changes after long-term treatment of at least 24 weeks or more [11,24]. In addition, the active GLP-1 levels-within the physiologic range- might not be sufficient to suppress α-cell activity after DPP4 inhibition. We did not determine glucagon levels in early phases (days to weeks), but the glucagon suppression effect of evogliptin may be dominant in the early phase after add-on; thus, further studies are required.

Despite of clinical relevance of the current study, our study has a few limitations. First, this study was conducted only with Korean patients, and the generalization of the results of this study to other ethnic groups may be limited. Especially, the glycemic efficacy of DPP4 inhibitors was shown greater in Asian than in other ethnicity [25], it might be different from evogliptin efficacy in other countries. In addition, the long-term effects and safety of more than 1 year cannot be guaranteed. However, our study has the strength to show the mechanisms of triple combination or evogliptin add-on therapy in poorly controlled T2DM patients.

In conclusion, evogliptin add-on therapy to DAPA/MET combination therapy showed a superior HbA1c reduction effect compared with that of placebo treatment without causing adverse events in patients with T2DM, demonstrating a good alternative combination therapy for patients with poor glycemic control.

SUPPLEMENTARY MATERIALS
Supplementary materials related to this article can be found online at https://doi.org/10.4093/dmj.2022.0387.

CONFLICTS OF INTEREST
Kyu Chang Won has been honorary editor of the Diabetes & Metabolism Journal since 2020. Jun Sung Moon has been associate editor of the Diabetes & Metabolism Journal since 2022. They were not involved in the review process of this article. Otherwise, there was no conflict of interest.

AUTHOR CONTRIBUTIONS
Conception or design: K.C.W., K.H.Y.
Drafting the work or revising: J.S.M., I.R.P.

ORCID
Jun Sung Moon https://orcid.org/0000-0003-1569-3068
Il Rae Park https://orcid.org/0000-0003-4436-0158
Kun-Ho Yoon https://orcid.org/0000-0002-9109-2208

FUNDING
This study was supported by Dong-A ST Co. Ltd., Seoul, Republic of Korea. The sponsor participated in the study design, data collection, and analysis of the data. The sponsor had no role in writing the manuscript and in the decision to submit the manuscript for publication.

ACKNOWLEDGMENTS
We thank the other investigators for their cooperation in this study. The list of the other investigators in this study is as follows: Sung Rae Kim (Department of Internal Medicine, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea), In Kyung Jeong (De-
REFERENCES


16. Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combina-
SUPPLEMENTARY METHODS

Inclusion/exclusion criteria

Inclusion criteria

(1) Male and female patients with type 2 diabetes mellitus aged 19 years or older.
(2) Participants who underwent dual therapy (fixed-dose combination product allowed) for one of the following, along with diet and exercise therapy:
   1) Those taking metformin ≥1,000 mg/day and dapagliflozin 10 mg/day at the same dose for at least 8 weeks before the screening visit (Visit 1).
   2) Those taking metformin ≥1,000 mg/day and sodium-glucose cotransporter 2 (SGLT2) inhibitor except for dapagliflozin at the same dose for at least 8 weeks before the screening visit (Visit 1).
(3) Participants with 7.0% ≤ glycosylated hemoglobin (HbA1c) level ≤ 10.5% at the screening visit (Visit 1, Visit 1-1).
(4) Participants with fasting plasma glucose level ≤ 270 mg/dL at the screening visit (Visit 1).
(5) Participants with 18.5 kg/m² ≤ body mass index ≤ 40 kg/m² at the screening visit (Visit 1).
(6) Those who voluntarily decided to participate in the study and signed a written informed consent form after listening to and fully understanding the detailed explanation of this clinical trial.

Exclusion criteria

(1) Participants with type 1 diabetes mellitus, secondary diabetes, gestational diabetes, diabetic ketoacidosis, diabetic coma, diabetic pre-coma, lactic acidosis, and acute or chronic metabolic acidosis.
(2) Participants with hypopituitarism or adrenal insufficiency, pulmonary infarction, severe pulmonary dysfunction, and other conditions prone to accompany hypoxemia.
(3) Participants with severe infectious disease or severe traumatic systemic disorder.
(4) Those with end-stage renal disease or undergoing dialysis.
(5) Participants with genetic diseases of galactose intolerance, Lapp lactase deficiency, and glucose-galactose malabsorption.
(6) Participants with liver cirrhosis, chronic active hepatitis B or C, cholecystitis, acromegaly, asthma, or major skin allergies.
(7) Participants with thyroid dysfunction requiring drug therapy with thyroid stimulating hormone levels outside the normal range at the screening visit (Visit 1). However, those treated with stable thyroid hormone replacement therapy for at least eight weeks before the screening visit (Visit 1) were allowed to enroll.
(8) Participants with gastrointestinal disorders such as dehydration, diarrhea, and vomiting at the screening visit (Visit 1).
(9) Participants with a history of resection of more than half of the stomach or small intestine, heart failure of New York Heart Association (NYHA) class III or greater, acute and unstable heart failure, and congestive heart failure.
(10) Participants with a history of hypersensitivity to the components of clinical investigational products, dipeptidyl peptidase 4 (DPP4) inhibitors, SGLT2 inhibitors, metformin, or glimepiride.
(11) Participants with a history of bariatric-metabolic surgery within 1 year prior to the screening visit (Visit 1).
(12) Participants with a history of uncontrolled arrhythmia, unstable angina, myocardial infarction, stroke, transient ischemic attack, coronary artery bypass grafting, coronary intervention, or cerebrovascular disease within 3 months prior to the screening visit (Visit 1).
(13) Participants with a weight change of more than 10% within 3 months prior to the screening visit (Visit 1).
(14) Participants who underwent surgery (minor surgery with no restriction on food and fluid intake) within 4 weeks prior to the screening visit (Visit 1) or scheduled to undergo surgery (minor surgery with no restriction on food and fluid intake) during the clinical trial period.
(15) Participants with one or more of the following findings in the clinical laboratory tests conducted at the time of the screening visit (Visit 1):
   1) Positive for anti-human immunodeficiency virus (HIV) antigen test.

https://e-dmj.org Diabetes Metab J 2023 Forthcoming. Posted online 2023
2) Aspartate transaminase (AST) or alanine transferase (ALT) level > upper normal limit (UNL) × 3.

3) Fasting triglyceride level was 500 mg/dL or more.

4) Estimated glomerular filtration rate (Modification of Diet in Renal Disease [MDRD] formula) was less than 45 mL/min/1.73 m².

5) Participants with a creatine phosphokinase of 2.5 times greater than the ULN and accompanying symptoms such as dyspnea and chest pain.

(16) Participants who had taken insulin (allowed to be enrolled if insulin was administered temporarily [14 days or less] owing to surgery or for examination), glucagon-like peptide 1 (GLP-1) receptor agonists, thiazolidinediones, or DPP4 inhibitors within 12 weeks prior to the screening visit (Visit 1).

(17) Participants who had taken sulfonylureas, meglitinides, or α-glucosidase inhibitors within 8 weeks prior to the screening visit (Visit 1).

(18) Participants who had taken drugs for weight loss within 12 weeks prior to the screening visit (Visit 1).

(19) Participants who had been administered systemic corticosteroids chronically (> 14 days) within 8 weeks prior to the screening visit (Visit 1).

(20) Participants who had undergone the radiological test with intravenous injection of iodinated contrast medium (e.g., intravenous urography, intravenous cholangiography, angiography, and computed tomography using a contrast medium).

(21) Participants taking oral contraceptives (allowed if taking the same dose for at least 8 weeks before the screening visit to treat menopausal symptoms), warfarin, digoxin, strong CYP3A4 inhibitors, strong CYP3A4 inducers, organic cation transporter (OCT) inhibitors, or OCT inducers at the screening visit (Visit 1).

(22) Participants who had taken other investigational products within 4 weeks prior to the screening visit (Visit 1).

(23) Participants with a history of malignancy within 5 years prior to the screening visit (Visit 1).

(24) Participants with a history of drug or alcohol abuse, or other substance abuse within 6 months prior to the screening visit (Visit 1).

(25) Pregnant or lactating women and women of childbearing age who cannot consent to contraception by methods other than oral contraceptives.

*Methods other than oral contraceptives include physical barrier methods, including condoms, contraceptive diaphragms, or cervical caps.

(26) Participants with physical (such as severe disorders in the liver, heart, kidney, lung, hematological, endocrine, musculoskeletal, and gastrointestinal system) or mental (cognitive disorders, mental illness) conditions that may interfere with the ability to participate in the study.

(27) Others, such as participants evaluated as ineligible at the discretion of investigators, such as those with severe complications of diabetes.

Secondary endpoints

Main study: Change from baseline after 24 weeks or ratio at 24 weeks
Extension study: Change from baseline after 52 weeks or ratio at 52 weeks

(1) HbA1c level (%) at 52 weeks
(2) Fasting plasma glucose level (mg/dL)
(3) HbA1c response rate (less than 7.0%, less than 6.5%)
(4) 7-point self-monitoring blood glucose parameters: mean daily glucose level (mg/dL), postprandial glucose level (mg/dL) at 2 hours after breakfast/lunch/dinner, glycemic excursion (mg/dL)
(5) Fasting insulin, fasting proinsulin, glucagon, C-peptide, and adiponectin levels and proinsulin-to-insulin ratio
(6) Homeostatic model assessment of β-cell function (HOMA-β), homeostatic model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI)
(7) Rescue therapy rate
(8) Fasting lipid parameters (total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride, and free fatty acids)
(9) AST, ALT, and γ-glutamyltransferase
(10) Ketone body (total ketone, acetoacetate, and β-hydroxybutyric acid)
(11) Urine albumin creatinine ratio (UACR) and N-acetyl-β-D-glucosaminidase (NAG)
(12) High-sensitivity C-reactive protein
(13) Body weight
(14) General food craving questionnaire-trait (G-FCQ-T) score
### Supplementary Table 1. Results of secondary endpoints

<table>
<thead>
<tr>
<th>Variable</th>
<th>LS mean ± SE from baseline</th>
<th>LS mean difference between groups (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=141)</td>
<td>Evogliptin (n=140)</td>
<td>Evogliptin-Placebo</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>–0.17±0.93</td>
<td>0.24±0.92</td>
<td>0.41±1.29 (–2.14 to 2.96)</td>
</tr>
<tr>
<td></td>
<td>0.88±1.06</td>
<td>0.24±1.03</td>
<td>–0.63±1.47 (–3.52 to 2.25)</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>0.54±0.69</td>
<td>–0.22±0.68</td>
<td>–0.76±0.96 (–2.64 to 1.13)</td>
</tr>
<tr>
<td></td>
<td>–0.94±0.85</td>
<td>–1.12±0.82</td>
<td>–0.18±1.17 (–2.49 to 2.13)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>5.32±2.49a</td>
<td>2.19±2.48</td>
<td>–3.14±3.47 (–9.96 to 3.69)</td>
</tr>
<tr>
<td></td>
<td>5.93±2.49a</td>
<td>2.55±2.38</td>
<td>–3.38±3.39 (–10.05 to 3.28)</td>
</tr>
<tr>
<td>LDL-C, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>1.72±2.00</td>
<td>1.54±2.00</td>
<td>–0.17±2.79 (–2.53 to 0.77)</td>
</tr>
<tr>
<td></td>
<td>1.03±2.16</td>
<td>–0.18±2.06</td>
<td>–1.21±2.95 (–7.02 to 4.60)</td>
</tr>
<tr>
<td>HDL-C, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>2.02±0.60b</td>
<td>1.14±0.60</td>
<td>–0.88±0.84 (–2.53 to 0.77)</td>
</tr>
<tr>
<td></td>
<td>1.81±0.62b</td>
<td>–0.37±0.58</td>
<td>–2.18±0.84 (–3.83 to –0.53)</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>8.40±10.14</td>
<td>–7.21±10.12</td>
<td>–15.61±14.12 (–43.40 to 12.18)</td>
</tr>
<tr>
<td></td>
<td>–6.13±7.26</td>
<td>10.55±6.73</td>
<td>16.69±9.60 (–2.20 to 35.58)</td>
</tr>
<tr>
<td>Free fatty acids, mg/dL</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>0.12±19.59</td>
<td>–31.03±19.54</td>
<td>–31.15±27.27 (–84.85 to 22.54)</td>
</tr>
<tr>
<td></td>
<td>–13.95±21.75</td>
<td>–43.33±20.09a</td>
<td>–29.38±29.12 (–86.72 to 27.96)</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>–0.62±0.20b</td>
<td>–0.03±0.20</td>
<td>0.59±0.28 (0.05 to 1.13)</td>
</tr>
<tr>
<td></td>
<td>–0.88±0.26b</td>
<td>–0.30±0.24</td>
<td>0.57±0.35 (–0.12 to 1.27)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>–0.03±0.14</td>
<td>–0.22±0.14</td>
<td>–0.19±0.20 (–0.58 to 0.21)</td>
</tr>
<tr>
<td></td>
<td>–0.11±0.18</td>
<td>–0.03±0.17</td>
<td>0.07±0.25 (–0.42 to 0.56)</td>
</tr>
<tr>
<td>QUICKI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>0.00±0.00</td>
<td>0.00±0.00</td>
<td>0.00±0.00 (–0.00 to 0.01)</td>
</tr>
<tr>
<td></td>
<td>0.00±0.00</td>
<td>–0.00±0.00</td>
<td>–0.00±0.00 (–0.01 to 0.00)</td>
</tr>
<tr>
<td>Glucagon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from baseline at week 24</td>
<td>–0.76±0.29</td>
<td>–0.50±0.29</td>
<td>0.26±0.40 (–0.52 to 1.04)</td>
</tr>
<tr>
<td></td>
<td>–0.76±0.40</td>
<td>–0.36±0.39</td>
<td>0.39±0.55 (–0.70 to 1.48)</td>
</tr>
</tbody>
</table>

Testing for the difference between treatment groups (the mixed effect model repeated measure analysis).

LS, least square; SE, standard error; CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment of insulin resistance; QUICKI, quantitative insulin sensitivity check index.

*P<0.05, bP<0.01.
### Supplementary Table 2. Summary of TEAEs/AESIs and incidence of AESIs by system organ class and preferred term

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo (n=141)</th>
<th>Evogliptin (n=141)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with TEAEs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>32 (22.70) [48]</td>
<td>39 (27.66) [61]</td>
<td>0.4105</td>
</tr>
<tr>
<td>52 weeks</td>
<td>48 (34.04) [80]</td>
<td>50 (35.46) [101]</td>
<td>0.9005</td>
</tr>
<tr>
<td>Subjects with AESIs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 weeks</td>
<td>3 (2.13) [4]</td>
<td>4 (2.84) [5]</td>
<td>1.0000</td>
</tr>
<tr>
<td>52 weeks</td>
<td>4 (2.84) [5]</td>
<td>4 (2.84) [6]</td>
<td>1.0000</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>3 (2.13) [3]</td>
<td>1 (0.71) [2]</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>3 (2.13) [3]</td>
<td>1 (0.71) [2]</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>1 (0.71) [1]</td>
<td>2 (1.42) [3]</td>
<td></td>
</tr>
<tr>
<td>Lipase increased</td>
<td>1 (0.71) [1]</td>
<td>1 (0.71) [2]</td>
<td></td>
</tr>
<tr>
<td>Lipase abnormal</td>
<td>0 [0]</td>
<td>1 (0.71) [2]</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>1 (0.71) [1]</td>
<td>1 (0.71) [1]</td>
<td></td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>1 (0.71) [1]</td>
<td>1 (0.71) [1]</td>
<td></td>
</tr>
</tbody>
</table>

Values are presented as number of subject (percentage of subject) [number of event]. Difference between treatment groups was analyzed using the Fisher’s exact test.

TEAE, treatment-emergent adverse event; AESI, adverse event of special interest.